DE69129070D1 - Behandlung von tumorogenen pathophysiologischen zuständen durch verwendung von f4f-cytotoxinkonjugaten - Google Patents

Behandlung von tumorogenen pathophysiologischen zuständen durch verwendung von f4f-cytotoxinkonjugaten

Info

Publication number
DE69129070D1
DE69129070D1 DE69129070T DE69129070T DE69129070D1 DE 69129070 D1 DE69129070 D1 DE 69129070D1 DE 69129070 T DE69129070 T DE 69129070T DE 69129070 T DE69129070 T DE 69129070T DE 69129070 D1 DE69129070 D1 DE 69129070D1
Authority
DE
Germany
Prior art keywords
tumorogenic
treatment
pathophysiological states
cytotoxin conjugates
cytotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69129070T
Other languages
English (en)
Other versions
DE69129070T2 (de
Inventor
Paul Calabresi
Julie Beitz
Jeffrey Clark
A Frackelton
Douglas Lappi
Andrew Baird
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ROGER WILLIAMS GENERAL HOSPITAL PROVIDENCE RHODE ISLAND US
Roger Williams General Hospital
Salk Institute for Biological Studies
Original Assignee
ROGER WILLIAMS GENERAL HOSPITAL PROVIDENCE RHODE ISLAND US
Roger Williams General Hospital
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ROGER WILLIAMS GENERAL HOSPITAL PROVIDENCE RHODE ISLAND US, Roger Williams General Hospital, Salk Institute for Biological Studies filed Critical ROGER WILLIAMS GENERAL HOSPITAL PROVIDENCE RHODE ISLAND US
Application granted granted Critical
Publication of DE69129070D1 publication Critical patent/DE69129070D1/de
Publication of DE69129070T2 publication Critical patent/DE69129070T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69129070T 1990-09-19 1991-09-13 Behandlung von tumorogenen pathophysiologischen zuständen durch verwendung von f4f-cytotoxinkonjugaten Expired - Fee Related DE69129070T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58531990A 1990-09-19 1990-09-19
PCT/US1991/006680 WO1992004918A1 (en) 1990-09-19 1991-09-13 Treatment of tumorigenic pathophysiological conditions with fgf-cytotoxic conjugates

Publications (2)

Publication Number Publication Date
DE69129070D1 true DE69129070D1 (de) 1998-04-16
DE69129070T2 DE69129070T2 (de) 1998-08-20

Family

ID=24340934

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69129070T Expired - Fee Related DE69129070T2 (de) 1990-09-19 1991-09-13 Behandlung von tumorogenen pathophysiologischen zuständen durch verwendung von f4f-cytotoxinkonjugaten

Country Status (5)

Country Link
EP (1) EP0552188B1 (de)
JP (1) JPH06501005A (de)
CA (1) CA2089820C (de)
DE (1) DE69129070T2 (de)
WO (1) WO1992004918A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635384A (en) * 1990-06-11 1997-06-03 Dowelanco Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
GB9203533D0 (en) * 1992-02-19 1992-04-08 Erba Carlo Spa Use of the conjugate between a fibroblast growth factor and a saporin in treating ocular pathologies
US5916772A (en) * 1992-06-16 1999-06-29 Whittier Institute For Diabetes And Endocrinology Recombinant production of saporin-containing proteins
ES2091018T3 (es) * 1992-06-18 1996-10-16 Whittier Inst Diabetes & Endoc Procedimiento para la deteccion de enfermedades neoplasicas.
EP0712314A1 (de) * 1993-08-02 1996-05-22 Prizm Pharmaceuticals, Inc. Monogene bereitung von zytotoxische konjugaten
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
WO1995024928A2 (en) * 1994-03-15 1995-09-21 Prizm Pharmaceuticals, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
EP0923387B1 (de) * 1996-06-24 2001-09-26 Selective Genetics, Inc. Heparin-beschichtete medizinische geräte zum intravenösen gebrauch, die heparin-bindende wachstumfaktor-konjugate enthalten
PL238516B1 (pl) * 2016-06-13 2021-08-30 Univ Wroclawski Sposób otrzymywania modyfikowanego polipeptydu

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5191067A (en) * 1989-04-27 1993-03-02 The Salk Institute For Biological Studies Fibroblast growth factor conjugates

Also Published As

Publication number Publication date
WO1992004918A1 (en) 1992-04-02
CA2089820C (en) 1999-01-19
DE69129070T2 (de) 1998-08-20
CA2089820A1 (en) 1992-03-20
EP0552188A1 (de) 1993-07-28
EP0552188B1 (de) 1998-03-11
JPH06501005A (ja) 1994-01-27

Similar Documents

Publication Publication Date Title
DE68920775D1 (de) Behandlung von faserigen Materialien.
DE69114610D1 (de) Herstellung von n-phosphonomethylglyzin durch oxydation von n-phosphonomethyliminodiessigsäure.
DE69121788D1 (de) Herstellung von Aluminoxanen
DE68909219D1 (de) Behandlung von obesitas.
DE69117356D1 (de) Herstellung von Aluminoxanen
DE69211189D1 (de) Herstellungsverfahren von Siloxanzusammensetzungen
DE69102552D1 (de) Verfahren zur Behandlung von Fasermaterialien.
DE3788057D1 (de) Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
DE69006854D1 (de) Anhaftende selbstverkapselnde spritzzusammensetzungen von bioregulatorischen agenzien.
DE69224173T2 (de) Behandlung von lignocellulosischen Materialien
DE69104947D1 (de) Verhütung von Kesselstein.
DE69103444D1 (de) Herstellung von Glasgegenständen.
DE69013999D1 (de) Siliconkautschukzusammensetzung zur Behandlung von Faserstrukturen.
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
DE69129070D1 (de) Behandlung von tumorogenen pathophysiologischen zuständen durch verwendung von f4f-cytotoxinkonjugaten
DE69117266D1 (de) Modifizierung von gelatine
IT1240773B (it) Perfezionamento composizioni pozzolaniche.
DE69133144D1 (de) Reaktor zur Behandlung von Wafern
DE69103693D1 (de) Behandlung von unterirdischen Formationen.
DE68923219D1 (de) Behandlung von Abfällen.
DE69325141D1 (de) Behandlung von lignozellulosehaltigen Materialien
DE69208387D1 (de) Herstellung von feuchtigkeitshärtenden Organosiloxanzusammensetzungen
DE69132054D1 (de) Behandlung von windelausschlag
DE69028631D1 (de) Behandlung von fasermaterialien
DE69108357D1 (de) Behandlung von verdünnten säurehaltigen Lösungen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee